Geoffrey Kim — Head of Oncology Strategic Combinations at Astrazeneca PLC

Dr. Geoffrey Kim has been the Head of Oncology Strategic Combinations at AstraZeneca PLC since July 17, 2017. Dr. Kim was employed with the US Food and Drug Administration (FDA) where he held an impressive tenure serving as the Director of Division of Oncology Products in the Office of Haematology Oncology Products since 2015. He was tasked with the evaluation and regulation of oncology drug products that were in development and approved for breast, genitourinary and gynecologic cancers. He was also involved with numerous cross-functional working groups, developing policies pertaining to in-vitro companion diagnostics, combination products and therapy dose optimisation strategies for cancer medicines. Dr. Kim began working at the FDA in 2010 as a Medical Officer in the Division of Oncology Products. He performed laboratory research at these institutions with a particular focus on cell adhesion molecules and cellular signaling. Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in molecular signalling and ovarian cancer. He received his Bachelor's Degree from UCLA, his medical degree at the New York Medical College and completed his residency in internal medicine at the Montefiore Medical Center.